Missed an IBD Medication Dose? What to Do for Pills, Injections, and Infusions

Missing a dose of an inflammatory bowel disease medication is common. A systematic review of oral IBD therapy found non-adherence rates ranging from 7 to 72 percent, with most studies reporting that 30 to 45 percent of patients were non-adherent. Forgetting a pill, sleeping through an injection day, or missing an infusion appointment happens to people who are otherwise careful about their treatment. What to do next depends on which medication you take, how it is delivered, and how much time has passed. This is a workflow for the hours after you realize a dose was missed: who to contact, what to record, and why the record matters later.

Contact the prescribing team before you change anything

The safest first move after a missed dose of IBD medication is to contact the team that prescribed it, meaning your gastroenterology office, your infusion center, or the specialty pharmacy that dispenses the drug. Prescribing information is written for the standard schedule and cannot account for how far off schedule you are, what else you take, or whether you are currently flaring. The FDA-approved labeling for adalimumab, for example, states that if a dose is missed, the dose should be administered as soon as possible and dosing resumed at the regular scheduled time, but that sentence assumes a routine maintenance context. A dose missed by six hours and a dose missed by three weeks are different clinical situations. Never double a dose to compensate, and never restart an induction sequence on your own. Both decisions belong to your prescriber.

Pills, injections, and infusions fail in different ways

Oral IBD medications are usually the most forgiving of a single missed dose and the least forgiving of a pattern. Mesalamine maintenance therapy is the clearest example. In a prospective cohort of patients with quiescent ulcerative colitis, those who were nonadherent had more than a fivefold greater risk of recurrence than adherent patients, with a hazard ratio of 5.5. Small-molecule drugs taken daily, such as upadacitinib at 45 mg once daily for induction and 15 mg once daily for maintenance in ulcerative colitis, have short half-lives, so drug levels drop quickly when doses are skipped.

Subcutaneous injections operate on longer intervals, which makes a single missed injection more noticeable in the schedule and easier to correct. Adalimumab maintenance for Crohn's disease and ulcerative colitis is 40 mg every other week, and ustekinumab maintenance is 90 mg subcutaneously every 8 weeks. A missed injection shifts every subsequent date, so your care team needs to tell you whether to inject now and reset the calendar or hold and resume on the original date.

Infusions add scheduling and staffing constraints that you cannot solve alone. A missed infusion appointment requires the infusion center to rebook, and in some cases requires the specialty pharmacy or benefit to be reauthorized before the drug can be released.

Why a delayed infusion is worth taking seriously

Delayed and skipped infusions are more frequent than most patients assume. A Canadian cohort study of infliximab found that 198 of 215 patients, or 92.1 percent, received at least one delayed maintenance infusion, with delay defined as a gap of more than 72 hours between the scheduled and actual date. The concern with long gaps is immunogenicity. In the ACCENT I analysis, antibodies to infliximab developed in 30 percent of patients given a single dose followed by episodic retreatment, compared with 10 percent on standard scheduled maintenance and 7 percent on escalated maintenance. A meta-analysis of 18 studies covering 3,326 patients found anti-infliximab antibody prevalence of 45.8 percent with episodic infusions versus 12.4 percent with maintenance dosing, and a relative risk of infusion reactions of 2.07 in antibody-positive patients.

One late infusion is not the same as episodic therapy, and this evidence should not be read as a reason to panic. It explains why infusion centers treat rebooking as urgent and why your gastroenterologist may want a drug level checked. AGA guidance supports reactive therapeutic drug monitoring in adults with active IBD on anti-TNF therapy to guide treatment changes, and a documented interruption is exactly the context in which that testing becomes informative.

What to write down before you call

The follow-up conversation goes faster when you arrive with specifics rather than an impression. Your care team is trying to establish how long the gap was, whether the drug is still at a working level, and whether anything about the situation is likely to repeat. Record the medication name and strength, the date and time the dose was actually due, the date and time you realized it was missed, and whether you have taken or injected anything since.

Add the reason. Running out of supply, a prior authorization lapse, a shipment that did not arrive, illness, travel, side effects, or simple forgetting all point toward different fixes, and the fix for a pharmacy problem is nothing like the fix for a tolerability problem.

Note your symptoms at the time of the missed dose as well. Whether you were in remission or already having increased stool frequency, urgency, blood, or pain changes how quickly the team will want to see you.

Keeping an accurate record over time

A single logged missed dose helps with one phone call. A running log changes the quality of every treatment decision that follows. Non-adherence in IBD is associated with more frequent flares and increased healthcare utilization costs, and the drivers most consistently identified are psychological distress, patients' beliefs about their medications, and the quality of the doctor-patient relationship rather than demographics. Those are things a conversation can address, but only if the pattern is visible.

When a gastroenterologist is deciding whether a biologic has genuinely failed, the difference between a drug that stopped working and a drug that was taken inconsistently is the single most important piece of context. NIDDK notes that medications do not cure Crohn's disease but can reduce inflammation and bring on and maintain remission, which depends on the drug actually reaching the body on schedule. A dated log of missed and delayed doses, the reasons behind them, and any drug levels drawn afterward gives your care team a factual timeline instead of a recollection, and it keeps a solvable supply or scheduling problem from being misread as treatment failure.